Lipid III-45 | 2096984-25-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Lipid III-45
• 英文别名: 9-[9-(2-butyloctanoyloxy)nonyl-(3-hydroxypropyl)amino]nonyl 2-butyloctanoate
• CAS: 2096984-25-5
• 化学式: C₄₅H₈₉NO₅
• 分子量: 724.2
• InChiKey: WKWZZCCOOBPOOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.8
• 重原子数：
  51
• 可旋转键数：
  43
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] DELIVERY OF TARGET SPECIFIC NUCLEASES<br/>[FR] ADMINISTRATION DE NUCLÉASES SPÉCIFIQUES À UNE CIBLE
  申请人：SANGAMO THERAPEUTICS INC

  公开号：WO2018107026A1

  公开（公告）日：2018-06-14

  Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.

  本发明描述了包含阳离子脂质和其他脂质的脂质纳米颗粒，以及包含工程核酸酶以促进核酸向细胞的转移。
• [EN] LIPID NANOPARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE NANOPARTICULES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018081480A1

  公开（公告）日：2018-05-03

  Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

  提供了改进的脂质纳米粒子配方。还提供了利用这些脂质纳米粒子传递治疗剂的方法以及它们的制备方法。
• Lipids and lipid nanoparticle formulations for delivery of nucleic acids
  申请人：Acuitas Therapeutics, Inc.

  公开号：US10166298B2

  公开（公告）日：2019-01-01

  Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构的化合物： 或其药学上可接受的盐、同系物或立体异构体，其中 R1、R2、R3、L1、L2、G1、G2 和 G3 如本文所定义。本发明还提供了化合物作为脂质纳米粒子制剂的组分用于递送治疗剂的用途、包含化合物的组合物及其使用和制备方法。
• NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS
  申请人：Acuitas Therapeutics Inc.

  公开号：EP3368507B1

  公开（公告）日：2022-12-07
• DELIVERY OF TARGET SPECIFIC NUCLEASES
  申请人：Sangamo Therapeutics, Inc.

  公开号：US20180185516A1

  公开（公告）日：2018-07-05

  Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.